BRAF V600E
BRAF V600E is a recurrent activating mutation in the BRAF that results in constitutive signaling through the MAPK signaling pathway.
BRAF V600E is a recurrent activating mutation in the BRAF that results in constitutive signaling through the MAPK signaling pathway. In cancer biology, this alteration is widely recognized as a driver event because it can promote cell growth and survival independent of normal upstream regulation. As a result, BRAF V600E has become an important molecular target across multiple tumor types, including melanoma, colorectal cancer, thyroid carcinoma, central nervous system tumors, and histiocytic/dendritic cell neoplasms.
Clinically, the mutation is especially relevant because it can identify tumors that may respond to targeted therapy with RAF and MEK inhibition, such as dabrafenib plus trametinib. However, resistance remains a major limitation, and recent work has continued to examine both innate and acquired resistance mechanisms, as well as strategies to improve mutation-selective targeting. In some disease settings, BRAF V600E also serves as a diagnostic and stratification marker, including in mismatch-repair deficient colorectal cancer and aggressive thyroid cancers.
Where the papers sit
8 papers from the last 6 months study BRAF V600E directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 3 observational · 2 human data · 2 preclinical · 1 unclassified
Themes one subject
Those 8 are all about one subject.
-
BRAF V600E Across Cancers
BRAF V600E is being addressed across melanoma, thyroid carcinoma, craniopharyngioma, histiocytic sarcoma and colorectal cancer. Work combines liquid-biopsy detection and monitoring with computational repurposing, sequence-guided inhibitor discovery and new B-RAF V600E compounds. Clinical reports focus on feasibility, practice patterns and durable responses to BRAF/MEK inhibition rather than a single standard approach. The shared subject is mutation-directed diagnosis and treatment across diverse tumour settings, with no clear common therapeutic direction yet.
Papers
The 8 papers from the last 6 months that study BRAF V600E directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
BRAF V600E Across Cancers (8)
- Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology. Acta oncologica (Stockholm, Sweden) · 9 Sept 2026 PMID 42714248
- GraphPert: A graph autoencoder framework for network-based drug repurposing using transcriptional signatures-A case study on melanoma. Computers in biology and medicine · 5 Sept 2026 PMID 42700516
- Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium. Journal of neuro-oncology · 14 Aug 2026 PMID 42599619
- Metastatic Colorectal Cancer Diagnosed Before Age 35: A Distinct Subset of Early-Onset Disease? International journal of cancer · 21 Jul 2026 PMID 42478130
- Rational Inhibitor Discovery for BRAFV600E Using PSeMut, a Sequence-Driven Model. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 6 Jul 2026 PMID 42406425
- Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center. Endocrine · 23 Jun 2026 PMID 42334691
- Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
- Design and Synthesis of Pyrimidino[4,5-d]Pyrimidine-Based Compounds as Potent B-RAF V600E Inhibitors. ChemMedChem · 28 May 2026 PMID 42208521
By study type
Observational studies and case reports (3)
- Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology. Acta oncologica (Stockholm, Sweden) · 9 Sept 2026 PMID 42714248
- Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium. Journal of neuro-oncology · 14 Aug 2026 PMID 42599619
- Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
Human data, design not indexed (2)
- GraphPert: A graph autoencoder framework for network-based drug repurposing using transcriptional signatures-A case study on melanoma. Computers in biology and medicine · 5 Sept 2026 PMID 42700516
- Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center. Endocrine · 23 Jun 2026 PMID 42334691
Preclinical: animal, cell and lab studies (2)
- Rational Inhibitor Discovery for BRAFV600E Using PSeMut, a Sequence-Driven Model. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 6 Jul 2026 PMID 42406425
- Design and Synthesis of Pyrimidino[4,5-d]Pyrimidine-Based Compounds as Potent B-RAF V600E Inhibitors. ChemMedChem · 28 May 2026 PMID 42208521
Unclassified: not yet indexed with MeSH (1)
- Metastatic Colorectal Cancer Diagnosed Before Age 35: A Distinct Subset of Early-Onset Disease? International journal of cancer · 21 Jul 2026 PMID 42478130
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-07-23. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.